Remdesivir drug trials show patients recovering from COVID-19 | Town Square | Palo Alto Online |

Town Square

Post a New Topic

Remdesivir drug trials show patients recovering from COVID-19

Original post made on Apr 30, 2020

Patients are recovering from COVID-19 when they are given the experimental drug remdesivir, according to two studies by Gilead Sciences and the National Institute of Allergy and Infectious Disease.

Read the full story here Web Link posted Wednesday, April 29, 2020, 3:00 PM

Comments (1)

2 people like this
Posted by pearl
a resident of another community
on Apr 30, 2020 at 1:54 pm

Read below about the drug remdesivir, manufactured by Gilead Sciences of Foster City, California. Gilead Sciences, Inc., is an American biopharmaceutical company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
(Web Link)

Participants treated with remdesivir recovered from the ravages of the COVID-19 virus on average 30 percent quicker than those receiving a placebo. Even Dr. Fauci is talking about it!

Who owns remdesivir, how much can they make, and how much does it cost?
The drug was originally developed for Ebola but has shown promise with COVID-19. Web Link


Don't miss out on the discussion!
Sign up to be notified of new comments on this topic.

Email:


Post a comment

Sorry, but further commenting on this topic has been closed.

Get fact-based reporting on the COVID-19 crisis sent to your inbox daily.

Despite opposition, Chick-fil-A lands in Redwood City with long lines
By Elena Kadvany | 35 comments | 6,538 views

Kids and sugar: A cautionary tale
By Sherry Listgarten | 7 comments | 2,050 views

Couples: Are you Committed to your Vows or Dysfunction?
By Chandrama Anderson | 1 comment | 1,912 views

Preparing for School
By Cheryl Bac | 0 comments | 787 views

Do peaceful protests do any good? How about the more violent ones?
By Diana Diamond | 6 comments | 615 views